SeaStar Medical Holding Corporation (ICU)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | 8-K (2026-05-13) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-25) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 | ||
| 10-Q | Q2-2025 | — | ||
| 10-Q | Q1-2025 | 8-K (2025-05-14) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2025-03-27) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-13) · 99.1 | ||
| 10-Q | Q2-2024 | — | ||
| 10-K/A | FY-2023 | |||
| 10-Q | Q1-2024 | 8-K (2024-05-14) · 99.1 | 8-K (2024-04-17) · 99.1 | ||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | 8-K (2023-11-22) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-08-15) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-05-16) · 99.1 | ||
| 10-K/A | FY-2022 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | ||
| Document and Entity Information | ||
| Statements | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) | — |
|
| Consolidated Balance Sheets | ||
| Condensed Consolidated Balance Sheets (current Period Unaudited) (P) | — |
|
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Changes In Stockholders' Equity (deficit) (unaudited) | — |
|
| Consolidated Statements of Changes In Stockholders' Deficit | ||
| Consolidated Statements of Changes In Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accounts Receivable, Net | — |
|
| Accrued Expenses | ||
| Award Timing Disclosure | — |
|
| Business Combination and Recapitalization | — |
|
| Commitments and Contingencies | ||
| Common Stock and Preferred Stock | — |
|
| Common Stock and Stock-based Compensation | — |
|
| Convertible Notes | ||
| Convertible Preferred Stock, Common Stock and Preferred Stock | — |
|
| Cybersecurity | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Description of Business | ||
| Equity Line of Credit | ||
| Equity Transactions | ||
| Fair Value Measurements | ||
| Forward Purchase Agreements | ||
| Government Loans | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Net Loss Per Share | ||
| Note 1 | ||
| Note 10 | ||
| Note 11 | ||
| Note 12 | ||
| Note 13 | ||
| Note 14 | ||
| Note 15 | ||
| Note 16 | — |
|
| Note 2 | ||
| Note 3 | ||
| Note 4 | ||
| Note 5 | ||
| Note 6 | ||
| Note 7 | ||
| Note 8 | ||
| Note 9 | ||
| Notes Payable | ||
| Pay Vs Performance Disclosure | ||
| Restatement of Previously Issued Consolidated Financial Statements | — |
|
| Restatement of Quarterly Unaudited Results | — |
|
| Revenues and Contract Obligations | ||
| Segment Reporting | ||
| Stock-based Compensation Awards | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||
| Trade Accounts Receivable | ||
| Warrants | ||